Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Xanthus Life Sciences Inc
Profile last edited on: 7/31/2008      CAGE:       UEI:

Business Identifier: Personalized cancer drugs
Year Founded
1994
First Award
2003
Latest Award
2005
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

300 Technology Square
Cambridge, MA 02139
   (617) 225-0522
   info@xanthus.com
   www.xanthus.com
Location: Single
Congr. District: 07
County: Middlesex

Public Profile

In May of 2008, Xanthus Life Sciences Inc was acquired by British firm Antisoma plc. Xanthus focuses on oncology development and aims to commercialize drugs with a test enabling personalized dosing of chemotherapeutic agents. Xanthus is focused to development and commercialization of anticancer and other compounds in conjunction with its phenotyping technology. Xanthus was founded on the belief that drugs are given to a person not to a disease. All people are different and hence require different treatments. Xanthus is dedicated to developing customized dosing regimens for drug therapies that are responsive to individual patientÂ’s requirements. Xanthus intends to improve the practice of medicine through the development of customized dosing regimens

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$149,800
Phase II Dollars
$2,443,903
Total Awarded
$2,593,703

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2005 2 NIH $2,593,703
Project Title: Acetylator-based Individualized Dosing of Amonadife

Key People / Management

  Brian Leyland-Jones -- Chief Executive Officer

  Alfred M Ajami -- Chief Scientific Officer

  Robert Boisjoli -- Chief Financial Officer

  Michael A Boss -- Chief Business Officer

  Robert L Capizzi -- Senior Vice President, Chief Medical Officer

  Richard T Dean -- Former Chief Executive Officer

  Charles K Grieshaber -- VP Drug Development

  John Lister-James -- Vice President, Development

  John A McCarthy Jr -- Senior Vice President, Chief Financial Officer

  J Kris Piper -- Vice President, Regulatory Affairs and Quality Assurance

Company News

There are no news available.